Clinical trials: Chordoma
Unruptured Intracranial Aneurysms, Pituitary Neuroendocrine Tumor
China Treatment Trial for Tumor in Sellar Region With Unruptured Intracranial Aneurysm
The goal of this observational study is to learn about the treatment strategies for tumor in sellar region with unruptured intracranial aneurysms in the Chinese population.
- Conditions
- Unruptured Intracranial Aneurysms, Pituitary Neuroendocrine Tumor, Craniopharyngioma, Meningioma
- Trial name
- ChTTSRUIA (NCT07809178)
- Testing
- Tumor resection followed by aneurysm treatment, Aneurysm treatment followed by tumor resection, Observation
- Where
- China
- Volunteers
- 608 people
- Sponsor
- Cheng sen
Synovial Sarcoma, Soft Tissue Sarcoma
A Study to Assess the Safety and Tolerability of CFT8634 in Locally Advanced or Metastatic SMARCB1-Perturbed Cancers, Including Synovial Sarcoma and SMARCB1-Null Tumors
This is an open-label, non-randomized, first-in-human Phase 1/2 study designed to evaluate the safety and tolerability of CFT8634 in subjects with synovial sarcoma and SMARCB1-null tumors who: have received prior systemic…
- Trial name
- NCT05355753
- Testing
- CFT8634
- Where
- 12 sites in United States
- Volunteers
- 49 people
- Sponsor
- C4 Therapeutics, Inc.
Pancreatic Cancer, Osteosarcoma
BLESSED: Expanded Access for DNG64-CAR-V for Advanced Pancreatic Cancer, Sarcoma and Carcinoma of Breast
Forty patients with pancreatic cancer, sarcoma and carcinoma of breast will receive DNG64-CAR-V intravenously or intratumorally at a dose of 1-4 x 10e11 colony forming units (cfu) or equivalent 1.0-6.0 x 10e10 Vector Copies (VC)…
- Conditions
- Pancreatic Cancer, Osteosarcoma, MPNST (Malignant Peripheral Nerve Sheath Tumor), Chondrosarcoma
- Trial name
- NCT04091295
- Testing
- DNG64-CAR-V
- Where
- United States
- Sponsor
- Aveni Foundation
Chordoma, Chondrosarcoma
Hypofractionated Protontherapy in Chordomas and Chondrosarcomas of the Skull Base
The project is planned as a phase II clinical trial with a low level of intervention, for the prospective evaluation of the clinical results of radical or adjuvant treatment by proton therapy in chordomas and chondrosarcomas of…
- Trial name
- NCT05861245
- Testing
- 5-fraction hipofractionated protontheray, 25-fraction hypofractionated proton therapy
- Where
- Spain
- Volunteers
- 20 people
- Sponsor
- Quironsalud
Bone Sarcoma, Chondrosarcoma
Comparing Carbon Ion Therapy, Surgery, and Proton Therapy for Management of Pelvic Sarcomas Involving the Bone
This study compares carbon ion therapy, surgery, and proton therapy to determine if one has better disease control and fewer side effects.
- Conditions
- Bone Sarcoma, Chondrosarcoma, Chordoma, Ewing Sarcoma of Bone
- Trial name
- NCT05033288
- Testing
- Electronic Health Record Review, Quality-of-Life Assessment
- Where
- 3 sites in United States
- Volunteers
- 72 people
- Sponsor
- Mayo Clinic
Chordoma
Sacral Chordoma: Surgery Versus Definitive Radiation Therapy in Primary Localized Disease
Comparative study on surgery versus definitive radiation therapy in primary localized sacral chordoma
- Trial name
- SACRO (NCT02986516)
- Testing
- Randomized Cohort, Prospective cohort
- Where
- 28 sites in Austria, Germany and 8 more
- Volunteers
- 100 people
- Sponsor
- Italian Sarcoma Group
Chordoma
QUILT-3.011 Phase 2 Yeast-Brachyury Vaccine Chordoma
This is a phase 2 clinical trial to determine whether the yeast-brachyury vaccine GI-6301 improves the effectiveness of radiation for patients with localized chordoma.
- Trial name
- NCT02383498
- Testing
- GI-6301 Vaccine (Yeast- Brachyury), Radiotherapy, wGT3X-BT Actigraph
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- NantCell, Inc.
Chordomas, Chondrosarcomas
Proton Radiation for Chordomas and Chondrosarcomas
The objectives of this study are 1) To evaluate the feasibility and acute side effects of proton therapy for chordomas and chondrosarcomas and 2) To evaluate clinical outcomes and long term side effects of proton beam radiation…
- Trial name
- NCT01449149
- Testing
- Proton Therapy
- Where
- United States
- Volunteers
- 54 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Chordoma
A Study of BL-B01D1 in Patients With Locally Advanced or Metastatic Chordoma
This is an open-label, multicenter phase II study to evaluate the safety, efficacy and pharmacokinetic characteristics of BL-B01D1 for Injection in patients with locally advanced or metastatic chordoma.
- Trial name
- NCT06787664
- Testing
- BL-B01D1
- Where
- China
- Volunteers
- 27 people
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
Chordoma
Nivolumab With or Without Stereotactic Radiosurgery in Treating Patients With Recurrent, Advanced, or Metastatic Chordoma
This phase I trial studies the side effects of nivolumab with or without stereotactic radiosurgery (SRS) in treating patients with chordoma that has come back or spread from where it started to other places in the body.
- Trial name
- NCT02989636
- Testing
- Laboratory Biomarker Analysis, Nivolumab, Stereotactic Radiosurgery
- Where
- 2 sites in United States
- Volunteers
- 21 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Chordomas, Chondrosarcomas
Proton Therapy for Chordomas and/or Chondrosarcomas
The purpose of this study is to collect information from medical records to see what effects proton beam radiation has on cancer and analyze possible side effects.
- Trial name
- CH01 (NCT00797602)
- Where
- United States
- Volunteers
- 189 people
- Sponsor
- University of Florida
Advanced or Metastatic Solid Tumors
A Dose Escalation/Expansion Study of ERAS-601 in Patients With Advanced or Metastatic Solid Tumors
To evaluate the safety and tolerability of escalating doses of ERAS-601 when administered as a monotherapy and in combination with other cancer therapies in study participants with advanced or metastatic solid tumors.
- Trial name
- FLAGSHP-1 (NCT04670679)
- Testing
- ERAS-601, Cetuximab, Pembrolizumab
- Where
- 14 sites in United States, Australia
- Volunteers
- 90 people
- Sponsor
- Erasca, Inc.
Life Threatening Diseases
Phase II Study of Imatinib Mesylate in Patients With Life Threatening Malignant Rare Diseases
Exploratory study to examine the effect(s) of Imatinib mesylate treatment on life threatening rare diseases with known associations to one or more Imatinib mesylate -sensitive tyrosine kinases, and to identify the contribution of…
- Trial name
- NCT00154388
- Testing
- Imatinib mesylate
- Volunteers
- 185 people
- Sponsor
- Novartis Pharmaceuticals
Malignant Rhabdoid Tumors (MRT), Rhabdoid Tumors of the Kidney (RTK)
A Study of Tazemetostat in Adult Participants With Soft Tissue Sarcoma
This study will include participants with various types of cancer known as soft-tissue sarcomas. Tissues that can be affected by soft tissue sarcomas include fat, muscle, blood vessels, deep skin tissues, tendons and ligaments.
- Conditions
- Malignant Rhabdoid Tumors (MRT), Rhabdoid Tumors of the Kidney (RTK), Atypical Teratoid Rhabdoid Tumors (ATRT), Selected Tumors With Rhabdoid Features
- Trial name
- NCT02601950
- Testing
- Tazemetostat
- Where
- 32 sites in United States, Australia and 7 more
- Volunteers
- 267 people
- Sponsor
- Epizyme, Inc.
Rhabdomyosarcoma, Malignant Peripheral Nerve Sheath Tumors
Trial of Dasatinib in Advanced Sarcomas
This study will examine the response rate and the 6-month progression-free survival rates of subjects with advanced sarcoma treated with dasatinib.
- Conditions
- Rhabdomyosarcoma, Malignant Peripheral Nerve Sheath Tumors, Chondrosarcoma, Sarcoma, Ewing's
- Trial name
- NCT00464620
- Testing
- Dasatinib
- Where
- 20 sites in United States
- Volunteers
- 366 people
- Sponsor
- Sarcoma Alliance for Research through Collaboration
Chordoma, Unresectable Malignant Neoplasm
QUILT-3.091 NANT Chordoma Vaccine vs Radiation in Subjects With Unresectable Chordoma.
QUILT 3.091 Chordoma Vaccine: Phase 1B/2 NANT Chordoma Vaccine vs Radiation in Subjects with Unresectable Chordoma.
- Trial name
- NCT03647423
- Testing
- Aldoxorubicin Hydrochloride, ALT-803, ETBX-051
- Where
- United States
- Sponsor
- ImmunityBio, Inc.
Chordoma
Hypoxia-positron Emission Tomography (PET) and Intensity Modulated Proton Therapy (IMPT) Dose Painting in Patients With Chordomas
Before radiation treatment is given to treat chordomas, CT and MRI scans are used to create a three dimensional picture of the tumor using x-rays.
- Trial name
- NCT00713037
- Testing
- Fluoromisonidazole-PET/CT
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Massachusetts General Hospital
Chordoma
Children and Adults With Chordoma
Background: Chordoma is a rare type of bone cancer. It occurs in the skull base or spine. Researchers want to study people with chordoma in different ways.
- Trial name
- NCT03910465
- Where
- United States
- Volunteers
- 300 people
- Sponsor
- National Cancer Institute (NCI)
Chordoma
Efficacy and Safety of Imatinib in Chordoma
Preliminary response data, observed by Casali (Cancer, 2004) with imatinib 800 mg/day in patients affected by chordoma, need to be confirmed by a Phase II study, whose primary endpoint will be the formal assessment of clinical…
- Trial name
- NCT00150072
- Testing
- imatinib
- Where
- 12 sites in Italy, Switzerland
- Volunteers
- 55 people
- Sponsor
- Novartis Pharmaceuticals
Brain Tumor, Recurrent
Photodynamic Therapy (PDT) for Recurrent Pediatric Brain Tumors
The goal of this proposal is to evaluate a new Photodynamic Therapy (PDT) modification which could revolutionize the treatment of brain tumors in children and adults.
- Trial name
- NCT01682746
- Testing
- Photofrin (porfimer sodium) & photodynamic therapy.
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Harry T Whelan, MD